2026 US Payer Landscape Brief — Zenvara
Prepared by Aisha Bello, Senior Director of Market Access. Distribution: VP Commercial, Launch Lead, HEOR Director, KAM leadership. Covers the top 25 commercial plans, the top 10 Medicare Part D plans, the largest Medicaid Managed Care plans, and the federal payer landscape (VA, DoD).
Executive summary
Zenvara enters 2026 with established formulary positions at most of the top 10 commercial plans following an aggressive Q4 2025 contracting cycle. The two notable exceptions are Aetna (tier 4 with step-therapy through pembrolizumab, effective Jan 1, 2026 — booked as a loss in the win/loss log) and Humana Gold Plus HMO (non-formulary, exception only). The Cigna win in November 2025 — preferred tier 3 with PA only, effective July 1, 2026 — is the largest single net-positive change in the Zenvara payer landscape this year.
Net price erosion across the book is modeled at 4-6% YoY, driven primarily by IRA Part D rebate restructuring. The top three PBMs (CVS Caremark, Express Scripts, OptumRx) collectively account for roughly 78% of commercial Zenvara lives covered; their 2026 NPF refreshes happen in late Q3 and represent the dominant near-term risk.
UnitedHealthcare remains the highest-leverage commercial negotiation — both the largest single payer by lives and the lowest-friction contracting counterpart. The recent operational change at UHC (PA turnaround drift from 4 to 9 days, observed in April and confirmed in the May 12 internal review) is the single most material near-term commercial risk.
Top 5 commercial plans by lives covered
1. UnitedHealthcare Group — 51M commercial lives (OptumRx). Zenvara position: tier 3 preferred with PA. Performance: -22% vs plan in April-May 2026 due to PA latency drift. Risk level: HIGH (acute operational issue).
2. Anthem/Elevance Health — 45M commercial lives (CarelonRx). Zenvara position: tier 3 with PA + ST. Performance: -3% vs plan. Risk level: MEDIUM (stable but Anthem renegotiation cycle Q3 2026).
3. CVS Health/Aetna — 24M commercial lives (CVS Caremark). Zenvara position: tier 4 with step-therapy effective Jan 1, 2026. Performance: stable but suppressed. Risk level: MEDIUM (step-edit appeal cycle ongoing; cannot escalate without re-opening 2026 contract).
4. The Cigna Group/Evernorth — 18M commercial lives (Express Scripts). Zenvara position: tier 3 preferred with PA only, effective July 1, 2026. Performance: ramping. Risk level: LOW (recent win, established relationship).
5. Humana — 17M commercial lives (Humana Pharmacy Solutions). Zenvara position: not on commercial formulary. Performance: minimal. Risk level: LOW (small commercial book; Humana's volume is concentrated in Part D).
Top 5 Medicare Part D plans by membership
UnitedHealthcare Medicare Advantage (Optum Rx): preferred tier with PA, 9.8M lives. Performance on plan.
Humana Gold Plus HMO (Humana Pharmacy Solutions): non-formulary, exception process only. 8.9M lives. Significant access gap; appeal cycle continues but unlikely to land in 2026.
Aetna Medicare (CVS Caremark): preferred tier with PA, 3.4M lives. Performance on plan.
Centene WellCare (Express Scripts): preferred tier with PA, 4.5M lives. Performance on plan.
Humana Walmart Value Rx (Humana Pharmacy Solutions): not pursued (low Zenvara fit, value-tier plan).
PBM market structure
Express Scripts (Cigna Group): 31% of US prescription claims. Zenvara NPF status: included tier 3 with PA, effective May 2026.
CVS Caremark (CVS Health): 26% of claims. Zenvara NPF status: included tier 3 with PA + ST through pembrolizumab.
OptumRx (UnitedHealth): 23% of claims. Zenvara NPF status: included tier 3 with PA. Same UHC-side PA workflow currently flagged for latency.
Humana Pharmacy Solutions: 8% of claims. Zenvara NPF status: limited to Aetna-aligned product books.
Prime Therapeutics (BCBS): 5% of claims. Zenvara NPF status: included tier 3 with PA at the 7 largest BCBS regional plans.
MedImpact: 3% of claims. Zenvara NPF status: included tier 3 with PA in regional Medicaid Managed Care contracts.
Medicaid Managed Care
Zenvara is included on Preferred Drug Lists in 21 states with step-edit through pembrolizumab in 14 of those. The Florida AHCA PDL refresh on May 11, 2026 moved Zenvara from preferred to non-preferred with mandatory step-edit — booked as a loss in the win/loss log. Internal monitoring of state PDL refreshes is weekly; the FL refresh landed on a Sunday and was not registered internally until the following Friday.
The largest Medicaid Managed Care plans are UnitedHealthcare Community Plan (7.2M), Anthem Medicaid (6.4M), Molina Healthcare (5.1M), Aetna Better Health (2.9M), and Centene WellCare (Medicaid; 4.5M). Combined Medicaid lives covered: approximately 26M.
Federal payers
VA National Formulary: Zenvara included as of February 2026, no restrictions beyond the standard VA oncology pathway. 9.0M veterans covered.
DoD TRICARE: Zenvara included effective January 2026, preferred tier with PA. 9.5M military beneficiaries covered.
340B coverage: standard 340B pricing applies. No 340B-specific contracting in place.
Pricing
Wholesale acquisition cost (WAC): $14,000 per 480mg vial. At Q6W dosing, annualized WAC per patient: $122,000.
Average commercial net price (after rebates): $93,200 per patient per year (gross-to-net 24%).
Average Medicare Part D net price: $84,500 per patient per year (gross-to-net 31%).
Average Medicaid net price: $61,200 per patient per year (gross-to-net 50%, including statutory Medicaid rebates).
Blended net price across the book: $87,400. Net revenue per patient is ultimately driven by mix; commercial-heavy quarters yield ~3% higher blended net than Medicare-heavy quarters.
IRA impact
Zenvara is a small-molecule biologic and therefore eligible for IRA Medicare Drug Price Negotiation Program on the standard 7-year post-approval timeline. Selection eligibility window opens January 1, 2032. The current modeling assumes Maximum Fair Price implementation effective 2034. See IRA Negotiation Impact Analysis (1G6…) for detail.
The near-term IRA effect is the Part D rebate restructuring (effective 2025 and 2026) which has reduced manufacturer rebate liability while increasing manufacturer responsibility in the catastrophic phase. Net impact on Zenvara Part D economics: approximately -3.5% to -4% per beneficiary YoY.
Negotiation cycle calendar
Q1 2026 (Jan-Mar): annual rebate true-ups with top 5 PBMs.
Q2 2026 (Apr-Jun): mid-year operational reviews (UHC operational issue addressed here).
Q3 2026 (Jul-Sep): 2027 NPF submissions due to Express Scripts (July 1), CVS Caremark (July 15), OptumRx (July 30).
Q4 2026 (Oct-Dec): contract renewals with Aetna (December effective Jan 1, 2027) and tactical pull-through on 2027 Medicare Part D bids (CMS bid cycle finalized August 2026).
Watch items for 2026
ESI 2027 NPF refresh: high probability (~70%) that ESI imposes a step-edit through pembrolizumab as part of the 2027 cycle. Mitigation: defensive clinical data package preloaded; subgroup analysis on PD-L1≥50% prepared by HEOR.
Anthem closed-formulary states: probability (~60%) that Anthem moves to closed formulary in 4 BCBS-aligned states (Indiana, Kentucky, Ohio, Virginia). Mitigation: KAM-led engagement with state P&T committees.
CMS PA workflow audit: CMS-issued guidance on Part D PA workflows is expected in Q3 2026; impact on Zenvara's Part D PA criteria unclear but likely manageable.
Cross-references
Formulary Win/Loss Log (1E7…), Payer Objection Handling Playbook (1F1…), IRA Negotiation Impact Analysis (1G6…), Zenvara US Launch Plan (1V3…).